Table 2.

Linear regression with peak log₁₀CIRP on day 0 to 4.

			Unadjusted		Adjusted
	N (%)	B	95% CI	p-value	B	95% CI	p-value
Örebro cohort
Mild disease1	12 (13)	ref	ref		ref	ref	ref
Non-severe hypoxemia2	48 (53)	0.15	-0.13 to 0.43	0.29	0.20	-0.07 to 0.46	0.15
Severe hypoxemia3	31 (34)	0.37	0.075-0.66	0.01	0.36	0.08-0.64	0.01
Age years*	56 (45-66)	0.008	0.001-0.014	0.02	0.009	0.003-0.15	<0.01
Women	33 (36)	ref	ref	ref	ref	ref	ref
Men	58 (64)	0.18	-0.14 to 0.37	0.07	0.21	0.003 to 0.02	0.02
Charlson score2	0 (0-1)*	0.038	-0.05 to 0.12	0.39	0.03	-0.06 to 0.11	0.55
Symtom duration3	11 (9-14)*	-0.018	-0.04 to 0.01	0.20	-0.02	-0.05 to 0.002	0.07
Umeå cohort
Mild disease	49 (63)	ref	ref	ref	ref	ref	ref
Non-severe hypoxemia	19 (24.5)	0.30	0.08 to 0.52	<0.01	0.36	0.13 to 0.60	<0.01
Severe hypoxemia	8 (10.5)	0.74	0.43 to 1.05	<0.01	0.80	0.45 to 1.1	<0.001
Age years*	54 (46-64)	0.009	0.002 to 0.02	0.02	0.01	-0.001 to 0.01	0.07
Women	34 (44)	ref	ref	ref	ref	ref	ref
Men	44 (56)	0.12	-0.10 to 0.33	0.28	0.01	-0.17 to 0.22	0.77
Charlson score4	0 (0-1)*	0.052	-0.11 to 0.21	0.52	0.01	-0.14 to 0.15	0.94
Symtom duration5	7.5 (6-10)*	0.001	-0.02 to 0.02	0.94	-0.12	- 0.03 to 0.01	0.19

¹Non-hospitalized patient, or hospitalized patient with no need of oxygen treatment.

²Conventional oxygen treatment, or high nasal flow oxygen (HFNO) treatment with FiO2 < 50%.

³HFNO with FiO2 ≥50%, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) treatment.

⁴per unit.

⁵days since debut of symptoms at enrolment.

*median (IQR).

Bold p-values are statistically significant.